Chicago, IL USA - Novotech, the leading Asia Pacific centred biotech CRO is sponsoring key oncology focussed expert events for ASCO: a pre-ASCO Summit with eChina Health, and a webinar panel discussion on accelerating development of advanced therapies with Endpoints. 

Meet with the Novotech team at ASCO here

Novotech, which has more than 15 senior executives and oncology leaders attending ASCO, is sponsoring the eChina Health pre-ASCO China Summit and Dinner. The Summit brings together world leaders in oncology for a 1-day series of expert presentations.

Novotech CEO Dr. John Moller will give the welcome address, Novotech Chief Commercial Officer Barry Murphy will present during the session on “Bringing Transformational Medicines to Patients Worldwide” and Novotech Head of China Andy Liu is a panellist on the “Future of China Biopharmaceutical” session.

Session topics include:
•    Showcase Novel Breakthrough Therapies from China
•    Bringing Transformational Medicines to Patients Worldwide 
•    Future of China Biopharmaceutical
•    China Clinical Oncology Breakthrough
•    Global Clinical Oncology Breakthrough (by ASCO Breakthrough Organizing Committee)

Location: 320 S. Canal St. The Platform Conference Center Chicago
Date: June 1
Time: 1-8.30pm (Central Time)
Register here

The Novotech ASCO expert webinar panel in partnership with Endpoints is titled "How to accelerate development in novel & advanced oncology therapies — from the starting line.”

Confirmed panelist include:
•    Dr. Vishal Navani, Consultant Medical Oncologist Tom Baker Cancer Centre, University of Calgary
•    Michele Gerber, CMO, Myeloid Therapeutics
•    Kedan Lin, Senior Vice President, Harbour Biomed
•    Prof Jayesh Desai, Medical Oncologist/Clinical Research Head, Early Drug Development, Peter MacCallum Cancer Centre
•    Dr. Patricia Mucci LoRusso, Director – Early Phase Clinical Trials Program, Associate Center Director – Experimental Therapeutics, Yale Cancer Center/Yale University

Some of the questions covered include:
•    What ways we are seeing technologies such as CAR-T, ADCs, Immunotherapies, and mRNAs advance and innovate oncology development?
•    How can we set up trials with the end game in mind? 
•    In what ways is Bayesian Data playing a role in early phase clinical trial design moving forward?
•    What are the key considerations to accelerate oncology clinical development timelines to support a global program strategy? 

Register here
Date: June 5
Time: 1.30-2.25 pm EST (Virtual Event)

Novotech, a biotech CRO with global footprint and more than 25 years of clinical trial and drug development consulting experience was this month selected for the prestigious CRO Leadership Award 2023 for exceeded biotech customer expectations.

Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. 

The company has been selected for the CRO Leadership Award 2023, benchmarked as a top 10 CRO among the world’s leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.


Novotech 是國際公認具有全球執行能力、首屈一指、以亞太地區為中心的生物科技領域受託研究機構 (CRO)。Novotech 是具備實驗室、第 I 期臨床試驗設施、藥物開發諮詢服務、以及美國食品藥物管理局 (FDA) 法規專業知識的臨床 CRO,擁有超過 5,000 個臨床試驗專案的經驗,包含第 I 期到第 IV 期臨床試驗和生體相等性研究。Novotech 主要服務的客戶群是在亞太地區、美國和歐洲進行臨床試驗的生物科技公司。Novotech 在全球擁有超過 3,000 名員工和 34 個辦公室據點。